Patents Examined by Irina Neagu
-
Patent number: 11957655Abstract: Provided are methods of treating various forms of hearing loss caused by aberrant calcium fluxes in auditory cells. The methods encompass the administration of agents which prevent abnormal calcium fluxes, stabilize SERCA2b activity, or prevent ER UPR apoptotic responses. The methods include therapeutic treatments of subjects suffering from hearing loss as well as preventative treatments which protect auditory cells from cell death, for example as caused by exposure to loud noise.Type: GrantFiled: October 22, 2016Date of Patent: April 16, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Elliott Sherr
-
Patent number: 11957684Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: April 16, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11952341Abstract: The invention discloses a method of preparing a high chiral purity lactam intermediate D comprising a step of reducing a compound C to lactam intermediate D in a solvent by hydrogenation reduction using a heavy metal catalyst and a chiral inducer. Brivaracetam can be prepared in a single step using the lactam intermediate D. The synthesis route is short, reaction conditions are mild, post-treatment is simple, reaction yield is high, chiral selectivity is good, and production cost is low. The conversion rate of the compound C in the reaction is 81%, and the DE value of the compound D is more than 99.0%, which is suitable for industrial production.Type: GrantFiled: December 17, 2018Date of Patent: April 9, 2024Assignees: YANGZHOU AORUITE PHARMACEUTICAL CO., LTD., YANGZHOU LIANAO BIOMEDICAL CO., LTD.Inventors: Zhenpeng Yu, Fei Xiao, Guoping Wang, Shuxian Qi, He Gao
-
Patent number: 11918583Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: March 5, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11919867Abstract: An 5-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)pentanoic compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: October 26, 2023Date of Patent: March 5, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11903910Abstract: The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, Skits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions.Type: GrantFiled: September 26, 2018Date of Patent: February 20, 2024Assignee: University of Florida Research Foundation, IncorporatedInventors: Laura Ranum, Tao Zu
-
Patent number: 11890375Abstract: The present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day. The present invention also provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives.Type: GrantFiled: July 28, 2021Date of Patent: February 6, 2024Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Ajay Jaysingh Khopade, Arindam Halder, Ankit Shaileshkumar Shah
-
Patent number: 11878960Abstract: Novel organic selenide compounds that can be used as a chemopreventive mixture against breast cancer. These compounds and compositions may be used alone or in conjunction with DPPD. Likewise, the present subject matter relates to the use of N, N?-Diphenyl-1,4-phenylenediamine (DPPD) as a synthetic antioxidant supplementation to enhance breast cancer complications.Type: GrantFiled: July 24, 2023Date of Patent: January 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Saadeldin Elsayed Ibrahim Shabaan, Mai Mostafa Khalaf Ali, Mohamed Gouda, Shady Gamal El-Sawah, Ibrahim Youssef, Sameh M. Shabana
-
Patent number: 11844840Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.Type: GrantFiled: May 31, 2022Date of Patent: December 19, 2023Assignee: IMBRIA PHARMACEUTICALS, INC.Inventor: Andrew D. Levin
-
Patent number: 11801251Abstract: The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present invention also relates to the use of said compounds in the treatment of cancer and as therapeutic agents for eukaryotic parasites and respective methods of treatment.Type: GrantFiled: January 5, 2021Date of Patent: October 31, 2023Assignee: HOCHSCHULE DARMSTADTInventors: Franz-Josef Meyer-Almes, Christian Meyners, Alexander Kleinschek, Patricia Haus
-
Patent number: 11793812Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: May 11, 2021Date of Patent: October 24, 2023Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11787786Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: August 19, 2021Date of Patent: October 17, 2023Assignee: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew D. Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
-
Patent number: 11771672Abstract: Provided is a method of reducing autoimmunity, including reducing an amount of self-reactive B cells in a subject expressing elevated levels of an autoantibody, wherein reducing includes administering 2-hydroxyoleic acid to the subject. Also provided is a method of treatment including administering 2-hydroxyoleic acid to a subject expressing elevated levels of an auto-antibody. Also provided is a method of promoting B cell tolerance, including promoting apoptosis of self-reactive B cells in a subject, wherein promoting includes administering 2-hydroxyoleic acid to the subject.Type: GrantFiled: November 15, 2018Date of Patent: October 3, 2023Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Chongmin Huan, Christopher Roman, Peiqi Ou
-
Patent number: 11766427Abstract: The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans.Type: GrantFiled: February 13, 2019Date of Patent: September 26, 2023Assignee: EUROPEAN MOLECULAR BIOLOGY LABORATORYInventors: Mihaela Pruteanu, Lisa Maier, Michael Kuhn, Peer Bork, Athanasios Typas, Kiran Raosaheb Patil, Georg Zeller
-
Patent number: 11723893Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.Type: GrantFiled: March 5, 2021Date of Patent: August 15, 2023Assignee: MEI Pharma, Inc.Inventor: Ofir Moreno
-
Patent number: 11717516Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.Type: GrantFiled: October 25, 2022Date of Patent: August 8, 2023Assignee: CereSpir IncorporatedInventors: Daniel G. Chain, Ronald Mueller
-
Patent number: 11701340Abstract: The present invention is directed to liquid pharmaceutical compositions comprising an active ingredient selected from the group consisting of rasagiline, ropinirole and a pharmaceutically acceptable salt thereof and a liquid vehicle. The present invention is further directed to methods of treating Parkinson's disease or one or more symptoms of Parkinson's disease comprising administering a liquid pharmaceutical composition of the present invention to a subject in need thereof.Type: GrantFiled: April 17, 2020Date of Patent: July 18, 2023Assignee: VICI HEALTH SCIENCES., LLCInventors: Anish Dhanarajan, Francesca Minale
-
Patent number: 11690828Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: November 7, 2017Date of Patent: July 4, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
-
Patent number: 11654129Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.Type: GrantFiled: January 5, 2021Date of Patent: May 23, 2023Assignee: THE WILLIAM M YARBROUGH FOUNDATIONInventor: Michael E. Silver
-
Patent number: 11590071Abstract: Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.Type: GrantFiled: July 6, 2021Date of Patent: February 28, 2023Assignee: KING ABDULAZIZ UNIVERSITYInventors: Imran Kazmi, Hemant Yadav, Fahad Fahad A. Al-Abbasi, Muhammad Shahid Nadeem, Hisham Altayeb, Muhammad Afzal, Gaurav Gupta, Abhay Raizaday